×
About 755,783 results

Natural History and Development of Spondyloarthritis
https://clinicaltrials.gov/ct2/show/NCT01422694

Jan 13th, 2023 - The purpose of this protocol is to study the natural history of spondyloarthritis (SpA) in children and adults. Spondyloarthritis encompasses a spectrum of immune-mediated inflammatory diseases that exhibit overlapping features, but differ from other types of inflammatory arthritis in genetic predisposition, pathogenesis, and outcome. Ankylosing spondylitis (AS), the most common form of SpA, fr...

Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
https://clinicaltrials.gov/ct2/show/NCT03880422

Jan 27th, 2023 - PRIMARY OBJECTIVES: I. Assess the effect of individualized nutrition and exercise counseling interventions on myokine expression and body composition in prostate cancer (PrCa) patients being treated with androgen deprivation therapy (ADT). SECONDARY OBJECTIVES: I. Determine any changes in muscle strength, respiratory muscle strength and functional capacity resulting from the nutrition and exerc...

Sarcopenic Obesity in Neurodisabilities
https://clinicaltrials.gov/ct2/show/NCT03863379

Jan 27th, 2023 - To describe the frequency and thresholds for sarcopenic obesity in neurodisabled persons and the fat and lean mass distribution based on various neurodisabilities

Study of Endocrine-Related Conditions and Physiology
https://clinicaltrials.gov/ct2/show/NCT03867448

Jan 27th, 2023 - This protocol is designed to allow inpatient and outpatient evaluation of adults with a variety of endocrine disorders for purposes of research and physician education in our accredited internal medicine endocrinology training programs. Participants will receive clinical care per standard of practice for their condition. Data collected from standard clinical practice will be retained for future...

Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance
https://clinicaltrials.gov/ct2/show/NCT03833934

Jan 27th, 2023 - SPACEWALK is an innovative remote consent and participation study using next-generation sequencing (NGS) of plasma cell-free DNA (cfDNA) to characterize resistance mechanisms arising in ALK-positive non-small cell lung cancer (NSCLC) after progression while on a next generation ALK tyrosine kinase inhibitor (TKI). Additionally, the study will capture the potential of genomic-driven resistance t...

Virtual Reality on Perception of Pain and Anxiety by Hysteroscopy
https://clinicaltrials.gov/ct2/show/NCT03827824

Jan 27th, 2023 - A Cochrane review (included 32 clinical trials and 3304 patients) concluded that there was no effective and safe treatment for pain relief in patients undergoing outpatient hysteroscopy. In the same way, The Gynecology and Obstetrics Spanish Society (SEGO) discourages the routine use of analgesics prior to the test or the use of local anesthesia or sedation, since neither improves the pain nor ...

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
https://clinicaltrials.gov/ct2/show/NCT03952585

Jan 27th, 2023 - PRIMARY OBJECTIVES: I. To demonstrate non-inferiority in terms of progression-free survival (PFS) of concurrent reduced-dose radiation therapy (RT) with cisplatin or concurrent reduced-dose radiation therapy with nivolumab to the current standard of care (standard-dose RT with cisplatin). (Phase II) II. To demonstrate co-primary endpoints of non-inferiority of PFS and superiority of quality of ...

The Multicenter Randomized HYpertension and VALUEs (HYVALUE) Trial
https://clinicaltrials.gov/ct2/show/NCT03028597

Jan 27th, 2023 - One in 3 US adults has hypertension and African Americans are disproportionately affected; almost 40% of non-Hispanic blacks have hypertension. Although the rates of uncontrolled hypertension have been decreasing in all groups, African Americans continue to have higher rates of uncontrolled hypertension compared to white Americans. The Institute of Medicine, World Health Organization and others...

Validation of Sleep Apnea Screening Device Phase II
https://clinicaltrials.gov/ct2/show/NCT03025464

Jan 27th, 2023 - An alternative to polysomnography (PSG), which is done overnight in a lab, is home sleep apnea testing (HSAT). Also known as out-of-center testing, HSAT has emerged as a more convenient and increasingly widely used method to screen for sleep apnea. HSAT records fewer signals for assessment, is less cumbersome than traditional PSG, and allows patients to spend the night at home, eliminating the ...

Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Haploidentical or Cord Blood Stem Cell Transplant
https://clinicaltrials.gov/ct2/show/NCT03941769

Jan 27th, 2023 - PRIMARY OBJECTIVES: I. To determine the safety and establish the optimal biologic dose of glycosylated recombinant human interleukin-7 (CYT107). SECONDARY OBJECTIVES: I. To determine the rate of cytomegalovirus (CMV), Epstein-Barr virus (EBV) and BK viral infections in umbilical cord blood stem cell transplantation (CBT) and haploidentical stem cell transplantation (haplo-SCT) patients who rece...

Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
https://clinicaltrials.gov/ct2/show/NCT03941860

Jan 27th, 2023 - PRIMARY OBJECTIVE: I. To determine whether escalating maintenance therapy with the addition of ixazomib citrate (ixazomib) to lenalidomide improves overall survival among patients who are MRD positive after approximately 1 year of lenalidomide maintenance following an early stem cell transplant (=< 12 months from diagnosis). SECONDARY OBJECTIVES: I. To establish whether progression-free surviva...

Apelin as a Potential Treatment for Chronic Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT03956576

Jan 27th, 2023 - The apelins are a family of peptides whose most abundant isoform is [Pyr1]apelin-13. This binds to a single G protein coupled receptor known as 'APJ', which is widely expressed particularly in endothelium and cardiomyocytes. Apelin is the most powerful inotropic agent discovered to date, and apelin infusion into healthy humans leads to endothelium-dependent vasodilatation and BP lowering. Given...

Controlled MAP in the Brain Injury Patient (COMAT Study)
https://clinicaltrials.gov/ct2/show/NCT03991052

Jan 27th, 2023 - In brain injury patients, the maintenance of MAP within a very narrow range is desired to avoid complications related to hypoperfusion (undertreatment) or hypertension (over treatment). However, the MAP needed to reach can vary over time based on intracranial pressure. Additionally, it is well know that the nurses in the Intensive care unit managed multiple patients simultaneously and cannot de...

Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704)
https://clinicaltrials.gov/ct2/show/NCT03992352

Jan 27th, 2023 - At baseline, standardized Geriatric Assessment (GA) tools incorporating subject reported data and bedside testing will be collected. HCT-Comorbidity Index (CI) scores will be assigned and C-reactive protein (CRP) and albumin will be measured locally. Serial measures at 3, 6, and 12 months for frailty, skilled facility admission, and quality of life (QOL) using PROMIS measures for physical funct...

Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs
https://clinicaltrials.gov/ct2/show/NCT04840550

Jan 27th, 2023 - This is a double-blind, randomized, active-controlled, phase 3 study. Subjects will be randomly assigned to one of the two treatment groups (tegoprazan 25 mg, lansoprazole 15 mg).

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03989466

Jan 27th, 2023 - PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of itacitinib in combination with alemtuzumab in patients with T-cell prolymphocytic leukemia (T-PLL). SECONDARY OBJECTIVES: I. To evaluate the event free survival (EFS) in patients (pts) with T-PLL treated with itacitinib in combination with alemtuzumab. II. To evaluate response complete remission (CR), complete remission without b...

Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension
https://clinicaltrials.gov/ct2/show/NCT03042988

Jan 27th, 2023 - Primary autonomic failure is a neurodegenerative condition characterized by loss of efferent sympathetic function and severe baroreflex impairment. The clinical hallmark of autonomic failure is disabling orthostatic hypotension, but at least half of patients are also hypertensive while lying down. This supine hypertension can be severe and associated with end-organ damage and worsening of ortho...

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
https://clinicaltrials.gov/ct2/show/NCT04847466

Jan 27th, 2023 - Background: Natural killer (NK) cells are an important component of an anti-tumor immune response. PD-L1 CAR-NK (PD-L1 t-haNKs) is an off the shelf, irradiated human, allogeneic, NK cell line that is frozen, shipped, thawed and then infused. PD-L1 CAR-NK cells have been engineered to have 3 adaptive modifications: Expression of a chimeric antigen receptor (CAR) targeting the tumor-associated an...

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
https://clinicaltrials.gov/ct2/show/NCT03059992

Jan 27th, 2023 - This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp in patients ≥ 18 years of age with a documented invasive and/or severe fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment. Patients will be treated with ibrexafungerp for up to 180 days. Treatment beyond 180 days and co...

Vitamin D Deficiency and Dysautonomia
https://clinicaltrials.gov/ct2/show/NCT03032328

Jan 27th, 2023 - The investigators approach will combine HUT testing coupled with autonomic testing that includes continuous blood pressure and HR measurements, Baroreflex Sensitivity and Hear Rate Variability, to establish objective autonomic profiles, along with vascular testing including Pulse Wave Velocity, Ankle Brachial Index at rest and measures of blood volume of different compartments, Systemic Vascula...